UPDATE: Stifel Initiates Coverage on Celladon Corporation with Buy Rating, $16 PT as Novel Gene Therapy Could Revolutionize Heart Failure Treatment

In a report published Monday, Stifel analyst Brian Klein initiated coverage on Celladon Corporation CLDN with a Buy rating and $16.00 price target. In the report, Stifel noted, “We are initiating coverage of Celladon Corporation (CLDN) with a Buy rating and $16 target price. Mydicar is a one-time infusion of a viral vector that transfers a SERCA2a gene into heart muscle cells with the intention of improving calcium regulation and improving function.” Celladon Corporation closed on Friday at $7.57.